Research location
Gera
Germany
Advertisement
Research activity in Gera
GermanyCureCurrent currently publishes aggregate city-level research activity for this location: 95 trials and 105 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Gera
95 linked trials · page 1 of 2A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEFNCT07761117 · 2026-08-24 · 1 site observation
RECRUITING
A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DMNCT07667803 · 2026-06-29 · 1 site observation
RECRUITING
Phase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus Apalutamide in Patients With Metastatic Hormone-sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment With Apalutamide: REINFORCE Trial.NCT07333066 · 2026-06-05 · 1 site observation
RECRUITING
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)NCT07361510 · 2026-03-12 · 1 site observation
RECRUITING
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung CancerNCT07222566 · 2026-01-06 · 1 site observation
RECRUITING
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast CancerNCT07173751 · 2025-10-30 · 1 site observation
RECRUITING
A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of RecurrenceNCT06830720 · 2025-02-20 · 1 site observation
RECRUITING
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung CancerNCT06712355 · 2025-02-03 · 1 site observation
RECRUITING
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung CancerNCT06712316 · 2025-01-07 · 1 site observation
RECRUITING
NIS to Examine the Effectiveness of TDC in Patients With Metastatic Non-squamous NSCLC and High-risk Genetic AlterationsNCT06494540 · 2024-06-28 · 1 site observation
RECRUITING
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung CancerNCT06203210 · 2024-05-21 · 1 site observation
RECRUITING
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic AlterationsNCT06357533 · 2024-04-11 · 1 site observation
RECRUITING
Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast CancerNCT05306041 · 2023-01-02 · 1 site observation
RECRUITING
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)NCT05633654 · 2022-12-12 · 1 site observation
RECRUITING
Real-world Study on Dapagliflozin Usage in Patients With Heart Failure (HF) in GermanyNCT06336330 · 2024-04-25 · 1 site observation
ACTIVE_NOT_RECRUITING
Early Genetic Identification of ObesityNCT06239064 · 2024-01-24 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine TherapyNCT05840211 · 2023-05-08 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast CancerNCT05514054 · 2022-10-04 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung CancerNCT05005273 · 2022-10-03 · 1 site observation
COMPLETED
A Clinical Study Evaluating Efficacy of Pirepemat on Falls Frequency in Patients With Parkinson's Disease (PD)NCT05258071 · 2022-06-15 · 1 site observation
COMPLETED
Open-label Trial in Parkinson's Disease (PD)NCT04760769 · 2021-02-24 · 1 site observation
COMPLETED
A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)NCT04622319 · 2020-12-04 · 1 site observation
ACTIVE_NOT_RECRUITING
First-line Palbociclib and Endocrine Therapy for Patients With HR+/HER2- Advanced Breast Cancer in the Real-world Setting.NCT04767594 · 2020-10-27 · 1 site observation
ACTIVE_NOT_RECRUITING
Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations (TEMPO-3)NCT04542499 · 2020-09-23 · 1 site observation
COMPLETED
A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive DisorderNCT04338321 · 2020-08-21 · 1 site observation
COMPLETED
Impact of eHealth Monitoring on Overall Survival in Patients With Metastatic NSCLC / Extensive-stage SCLC / Advanced TNBC Under First-line Treatment With Atezolizumab Plus ChemotherapyNCT03911219 · 2019-07-10 · 1 site observation
COMPLETED
Master Study of the Acticor/Rivacor ICDs/CRT-Ds and the Plexa ProMRI S DX LeadNCT03891329 · 2019-04-30 · 1 site observation
COMPLETED
Effect of Safinamide on Parkinson's Disease Related Chronic PainNCT03841604 · 2019-04-09 · 1 site observation
COMPLETED
Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic FailureNCT03829657 · 2019-02-22 · 1 site observation
TERMINATED
Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast CancerNCT03595592 · 2018-09-07 · 1 site observation
ACTIVE_NOT_RECRUITING
Safety and Efficacy of THN102 in Patients With Parkinson's Disease and Excessive Daytime SleepinessNCT03624920 · 2018-07-12 · 1 site observation
COMPLETED
The Effectiveness Of Atezolizumab In Patients With Locally-Advanced Or Metastatic Non-Small Cell Lung Cancer After Prior ChemotherapyNCT03559647 · 2018-05-30 · 1 site observation
COMPLETED
An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung CancerNCT03417037 · 2018-05-24 · 1 site observation
WITHDRAWN
Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-ANCT03447769 · 2018-03-16 · 1 site observation
TERMINATED
Comparison of Secukinumab 300 mg Combined With a Lifestyle Intervention to Secukinumab Alone for the Treatment of Moderate to Severe Psoriasis Patients With Concomitant Metabolic SyndromeNCT03440736 · 2018-02-28 · 1 site observation
COMPLETED
Assessment of Pacing Stimulus Conduction and Latency Measurements in CRT-D PatientsNCT03314675 · 2018-02-26 · 1 site observation
TERMINATED
Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (MK-3475-598/KEYNOTE-598)NCT03302234 · 2017-12-14 · 1 site observation
COMPLETED
A Non-interventional Study for Women With HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer to Evaluate the Real-world Effectiveness of Treatment Algorithms Beginning With Ribociclib + AI/FUL, or With Endocrine Therapy or Chemotherapy as First Line TreatmentNCT06311383 · 2017-10-09 · 1 site observation
COMPLETED
Study to Evaluate the Efficacy, Safety and Tolerability of PXT002331 (Foliglurax) in Reducing Motor Complications of Levodopa Therapy in Parkinson Disease's PatientsNCT03162874 · 2017-07-04 · 1 site observation
COMPLETED
A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604)NCT03066778 · 2017-05-02 · 1 site observation
COMPLETED
Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)NCT03040999 · 2017-04-05 · 1 site observation
COMPLETED
IPG Replacement Study (PREFERENCE-H)NCT02963259 · 2017-03-29 · 1 site observation
COMPLETED
Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)NCT03043872 · 2017-03-27 · 1 site observation
ACTIVE_NOT_RECRUITING
A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Participants With Early Alzheimer's DiseaseNCT02956486 · 2016-10-20 · 1 site observation
TERMINATED
Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients at Early Stage of the DiseaseNCT02847650 · 2016-10-17 · 1 site observation
TERMINATED
An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced CancersNCT02869789 · 2016-10-05 · 1 site observation
COMPLETED
Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)NCT02864992 · 2016-09-13 · 1 site observation
ACTIVE_NOT_RECRUITING
BI 425809 in Patients With Cognitive Impairment Due to Alzheimer's Disease.NCT02788513 · 2016-08-11 · 1 site observation
COMPLETED
Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology PracticeNCT02847728 · 2016-07-28 · 1 site observation
COMPLETED
BIO|MASTER.Ilivia Family / PlexaNCT02774616 · 2016-06-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.